GW Pharmaceuticals PLCGWP:LSE

438.00
9.50 / 2.12 %
224.64k
42.90%
0.7177
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 27 2015 17:10 GMT.
GWP:LSE is traded on the London Stock Exchange Alternative Investment Market (Aim)

Consensus recommendation

As of Feb 14, 2015, the consensus forecast amongst 3 polled investment analysts covering GW Pharmaceuticals plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 28, 2014. The previous consensus forecast advised investors to purchase equity in GW Pharmaceuticals plc.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy1
Outperform0
Hold1
Underperform0
Sell0
No opinion0

Share price forecast

The one analyst offering a 12 month price target expects GW Pharmaceuticals plc share price to fall to 380.00 in the next year from the last price of 438.00. View Full Financials

High-13.2 %380.00
Med-13.2 %380.00
Low-13.2 %380.00

Dividends

Dividend information is not available for GW Pharmaceuticals PLC. View Full Financials

Earnings history & estimates

On Feb 04, 2015, GW Pharmaceuticals plc reported 1st quarter 2015 losses of -0.014 per share.
The next earnings announcement is expected on May 11, 2015. View Full Interim Financials

Average growth rate-28.00 %

GW Pharmaceuticals plc reported annual 2014 losses of -0.070 per share on Dec 02, 2014. View Full Annual Financials

Average growth rate-61.50 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

GW Pharmaceuticals plc had 3rd quarter 2014 revenues of 7.61m. This missed the 467.84m consensus estimate of the 3 analysts following the company. This was 1.12% above the prior year's 3rd quarter results. View Full Interim Financials

Average growth rate+0.83 %

GW Pharmaceuticals plc had revenues for the full year 2014 of 30.05m. This was 10.08% above the prior year's results. View Full Annual Financials

Average growth rate+0.21 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.